

**REMARKS/ARGUMENTS**

**I. Status of Claims**

Claims 1-32 were originally filed. Claims 1-32 were subject to a Restriction Requirement. After response to the Restriction Requirement, claims 1-32 are elected for prosecution. Claims 1 and 2 are amended to correct typographical and punctuation mistakes. Claims 1 and 2 are amended to recite proper Markush groups. Claim 28 is amended to correct punctuation mistakes. Claim 28 is amended to recite a proper Markush group. Claims 29-32 are amended to make the claims clear and concise. New claims 33-49 are added. New claims 33-49 are directed to particular species of Formulae III and IV. No new matter has been added. Support for the claims may be found in the specification.

**II. Response to the Restriction Requirement**


The claims are restricted into eight groups. Applicants alert the Examiner that the group numbers are mis-numbered in the Restriction Requirement (there are two Group IVs), thus resulting in 7 groups. In its election, Applicants will assume the Groups are numbered I-VIII. Applicants elect Group VII for prosecution on the merits. The claims of Group VII are drawn to a process of modulating an Edg-7 receptor mediated biological activity with thiazole compounds when X is C; Y is C; and Z is C. Claims 1-32 fall within Group I. New claims 33-49 also fall within Group I.

The election of the claims of Group VII is made with traverse. The claims emerge from a common inventive concept; a process of modulating an Edg-7 receptor mediated biological activity with tetrazole compounds, a process of modulating an Edg-7 receptor mediated biological activity with triazole compounds, a process of modulating an Edg-7 receptor mediated biological activity with pyrazole compounds, a process of modulating an Edg-7 receptor mediated biological activity with imidazole or diazole compounds, a process of modulating an Edg-7 receptor mediated biological activity with thiadiazole compounds, a process of modulating an Edg-7 receptor mediated biological activity with oxadiazole compounds, a process of modulating an Edg-7 receptor mediated biological activity with thiazole compounds and a process of modulating an Edg-7 receptor mediated biological activity with

oxazole compounds. The Applicants respectfully submit that searching the process of modulating an Edg-7 receptor mediated biological activity with tetrazole compounds, the process of modulating an Edg-7 receptor mediated biological activity with triazole compounds, the process of modulating an Edg-7 receptor mediated biological activity with pyrazole compounds, the process of modulating an Edg-7 receptor mediated biological activity with imidazole or diazole compounds, the process of modulating an Edg-7 receptor mediated biological activity with thiadiazole compounds, the process of modulating an Edg-7 receptor mediated biological activity with oxadiazole compounds, the process of modulating an Edg-7 receptor mediated biological activity with thiazole compounds and the process of modulating an Edg-7 receptor mediated biological activity with oxazole compounds would not be an undue burden on the Examiner.

### **III. Response to the Election of Species Requirement**

The Examiner has required the Applicants to elect a single species and a disease condition in which the identity of each claim element is explicitly set forth. Applicants' elect compound 105 which is set forth below:



Applicants also elect cancer as the disease condition. Cancer includes but is not limited to ovarian cancer, peritoneal cancer endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer and prostate cancer.

Applicants submit that pending claims 1-32 and new claims 33-49 are readable on the elected species.

Appl. No. 10/760,002  
Amdt. dated June 23, 2006  
Restriction Requirement dated April 25, 2006

PATENT

Applicants respectfully submit that such elections are without prejudice and expressly reserve the right to prosecute the non-elected species and claims at a later stage.

**CONCLUSION**

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-442-1000.

Respectfully submitted,



Alok Goel (Reg. No. 51,745) on behalf of  
Thomas D. Kohler (Reg. No. 32,797)

MORGAN, LEWIS & BOCKIUS, LLP  
Two Palo Alto Square  
3000 El Camino Real, Ste. 700  
Palo Alto, CA 94306  
Tel. (415) 442-1000  
Direct Dial: (415) 442-1433  
eFAX: (650) 843-4001  
e-mail: agoel@morganlewis.com

1-SF/7373885.1